ANI Pharmaceuticals has completed the acquisition of the NDAs for purified corticotropin gel and corticotropin zinc hydroxide from Merck for $75m in cash and a percentage of future net sales.
Subscribe to our email newsletter
The acquisition was funded through cash on hand.
The assets were acquired from a Dutch subsidiary of Merck by ANI Pharmaceuticals C.V., a Netherlands based wholly owned indirect subsidiary of ANI.
ANI Pharmaceuticals president and CEO Arthur Przybyl said: "Having now closed the acquisition of the corticotrophin NDAs, we look forward to advancing our re-commercialization plan."